Exabis Library
Welcome to the e-CCO Library!
P406: Disease clearance in patients with ulcerative colitis treated with aminosalicylates
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P406: General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P406: Malnutrition during hospitalisation for acute severe IBD is associated with increased risk of relapse
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P406: Observational study of the effectiveness of vedolizumab on treatment outcomes and health-related quality of life in biologic-naïve patients with Inflammatory Bowel Diseases in Greece – the TROVE study - Interim Analysis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P407 Is the rapid infliximab infusion a safe and cost-saving strategy in paediatric inflammatory bowel disease?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P407: A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: An interim analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P407: Clinical manifestations of thiopurine S-methyltransferase variants in Korean paediatric patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P407: Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P407: Faecal calprotectin predicts sustained treatment response of infliximab induction therapy superior to C-reactive protein and clinical activity scores in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P407: Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centre
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P407: Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P407: Thiopurines: use them or lose them? Results of an international survey
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P408 Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P408: Anti-Drug Antibodies Detected in the Presence of Adequate Infliximab Drug Levels In IBD Patients in Clinical Remission have Limited Clinical Significance
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P408: Are pharmacokinetics more unfavourable in inflammatory bowel disease patients aged over 60 years?
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P408: Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experience
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P408: Faecal infliximab and disease activity in Acute Severe Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P408: Intestinal failure in Crohn’s disease: A case–control study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P408: Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in Norway
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P408: Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM